Saturday 17 October 2026
Export INMB’s income statement to Excel — free account
INmune Bio, Inc.
INMB Healthcare Biotechnology
INmune Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $50,000.00, up 257.1% from fiscal 2024. In the quarter to June 2026, revenue grew 8.70%, EPS grew 95.2% and free cash flow grew 55.4%, each against the same quarter a year earlier.
1.57
0.08
−4.85%
Follow INMB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(155.77%) | (165.16%) | (168.78%) | (74.82%) | |
| (115.83%) | (127.75%) | (130.78%) | (57.08%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (646.94%) | |
Return on Tangible Assets |
(206.22%) | (204.82%) | (226.87%) | (96.06%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.19) | (0.95) | (0.72) | (0.61) | |
Free Cash Flow |
(31.55) | (23.62) | (19.16) | (16.43) | |
Capital Expenditures |
(0.90) | (1.04) | — | (1.47) | |
| Other line items | |||||
Cash ROIC |
(59.40%) | (48.94%) | (46.75%) | (42.38%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.61 | 0.49 | 0.46 | 0.81 | |
Depreciation/Fixed assets |
0.08 | 0.11 | 0.16 | 0.16 | |
Capex/Depreciation |
(12.32) | (9.92) | 0.00 | (7.29) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.15) | (0.91) | (0.72) | (0.56) | |
Capex per Share |
(0.03) | (0.04) | 0.00 | (0.06) | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates